RxDoctor Payments Data

Oleksandr Seleverstov, MD

Internal Medicine · College Place, WANPI 1770841421

Payments from drug & device makers

$1,262in general payments, 2019–2025

Across 56 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$401
  • AbbVie$139
  • Abbott$134
  • GSK$106
  • Exact Sciences$90
  • Novo Nordisk$89
  • plus $303 from 10 others

What the payments were for

  • Food & beverage$1,262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,262 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$304,952
Medicare patients
301
Services billed
3,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$110,292
RybelsusSemaglutide31$59,185
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$54,716
JardianceEmpagliflozin40$51,543
CreonLipase/Protease/Amylase20$37,267
XareltoRivaroxaban22$26,709
Combivent RespimatIpratropium/Albuterol Sulfate25$19,404
EntrestoSacubitril/Valsartan18$15,120
TrulicityDulaglutide13$14,540
JanuviaSitagliptin Phosphate20$13,550
OzempicSemaglutide14$12,660
RectivNitroglycerin12$10,572
Gabapentin171$4,313
PaxilParoxetine Hcl12$3,770
Atorvastatin Calcium334$3,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$89$71,84645 claims
Boehringer IngelheimJardiance, Combivent Respimat$74$70,94865 claims
GSKTrelegy Ellipta$106$54,71647 claims
AbbVieCreon, Synthroid$139$39,14752 claims
NovartisEntresto$15$15,12018 claims
Lilly USA, LLCTrulicity$13$14,54013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in College Place

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →